Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02035189
Recruitment Status : Completed
First Posted : January 14, 2014
Last Update Posted : March 3, 2015
Sponsor:
Information provided by (Responsible Party):
University of Arkansas

Brief Summary:
An observational study in evaluating the clinical impact of procalcitonin on the care of Stem cell transplant recipient and its performance as an adjunct in the diagnosis and prognostication of Infectious processes

Condition or disease
Multiple Myeloma

Detailed Description:
The overall goal of this project will be to provide new insights into the use of biomarkers in surveillance for infectious processes in Stem Cell Transplant recipients by evaluating the added impact of procalcitonin testing on detection of infectious processes

Layout table for study information
Study Type : Observational
Actual Enrollment : 100 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients and Its Performance as an Adjunct in the Diagnosis and Prognostication of Infectious Processes
Study Start Date : October 2013
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Levels of Procalcitonin [ Time Frame: Daily up to 30 days ]
    Levels of Procalcitonin will be measured daily for a period not to exceed 30 days.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with Multiple Myeloma at UAMS receiving Stem Cell transplantation
Criteria

Inclusion Criteria:

  • Patients age 18-95 years with Multiple Myeloma (MM) undergoing stem cell transplantation

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02035189


Locations
Layout table for location information
United States, Arkansas
University of Arkansas for Medical Sciences
Little rock, Arkansas, United States, 72205
Sponsors and Collaborators
University of Arkansas
Investigators
Layout table for investigator information
Principal Investigator: Senu Apewokin, MD University of Arkansas
Study Director: Naveen Sanathkumar, MD University of Arkansas
Layout table for additonal information
Responsible Party: University of Arkansas
ClinicalTrials.gov Identifier: NCT02035189    
Other Study ID Numbers: 202342
First Posted: January 14, 2014    Key Record Dates
Last Update Posted: March 3, 2015
Last Verified: March 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases